1. Adalimumab Treatment Effects on Inflammation and Adipose Tissue Mitochondrial Respiration in Hidradenitis Suppurativa.
- Author
-
Sahl RE, Poggi AI, Nielsen VW, Yao Y, Patsi I, Poulsen SS, Dela F, Larsen S, Thomsen SF, and Helge JW
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Cell Respiration drug effects, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Macrophages metabolism, Tumor Necrosis Factor-alpha metabolism, Adalimumab therapeutic use, Adalimumab pharmacology, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa metabolism, Mitochondria metabolism, Adipose Tissue metabolism, Inflammation drug therapy
- Abstract
Objective: Tumour necrosis factor (TNF)-α is a proinflammatory marker and has been shown to affect mitochondrial function in different tissues. We investigated the effect on adipose tissue (AT) inflammation and mitochondrial respiration in patients with hidradenitis suppurativa (HS) after 12 weeks of treatment with adalimumab, a TNF-α inhibitor., Methods: We sampled blood and an AT biopsy from 13 patients with HS and 10 control subjects after an overnight fast. The patients were retested after at least 12 weeks of treatment with adalimumab (40 mg/week). We measured macrophage content and mitochondrial respiration in the AT and interleukin (IL)-1β, IL-6, IL-10, high-sensitivity C-reactive protein (hsCRP), interferon-γ, TNF-α, adiponectin and leptin in plasma. Clinical scores and Dermatology Quality of Life Index (DLQI) were assessed., Results: We found a higher anti-inflammatory macrophage content (CD206
+ ) in the patient group compared with the control group, but no differences between before and after the intervention. No difference in mitochondrial respiration was observed. We observed higher plasma IL-6 and hsCRP concentrations in patients with HS compared to controls, with no differences before and after the intervention. The difference between controls and HS patients was abolished after the intervention. HS patients improved their DLQI after the intervention with no change in clinical scores., Conclusion: Treatment with adalimumab in patients with HS does not alter AT inflammation or mitochondrial respiratory capacity; however, we did see a higher content of anti-inflammatory macrophages in the patient group compared with the control group., (© 2024 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF